Abstract P5-02-28: p27Kip1 V109G single-nucleotide polymorphism (SNP): pinpointing the hormone-receptor positive breast cancer subpopulation that requires CDK4/6 inhibitors in addition to endocrine therapy
Miguel Quintela-Fandiño(Spanish National Cancer Research Centre), Marcos Malumbres(Spanish National Cancer Research Centre), Manuel Muñoz(Spanish National Cancer Research Centre), Luís Manso(Research Institute Hospital 12 de Octubre), Silvana Mourón(Spanish National Cancer Research Centre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), María J. Bueno(Spanish National Cancer Research Centre), Sandra Rodríguez(Spanish National Cancer Research Centre), Jorge Silva(University of Lisbon), Raul M. Torres(Cancer Research Center)
Cited by 0
Related Papers
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
|Cancer Immunology Research|2019|181
DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy
|Journal of Clinical Oncology|2006|149
In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
|Nature Communications|2020|113